A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with less than or equal to 30% blasts

Authors :: Garcia-Manero, G
Sekeres, M A
Egyed, M
Breccia, M
Graux, C
Cavenagh, J D
Salman, H
Illes, A
Fenaux, P
DeAngelo, D J
Stauder, R
Yee, K
Zhu, N
Lee, J-H
Valcarcel, D
MacWhannell, A
Borbenyi, Z
Gazi, L
Acharyya, S
Ide, S
Marker, M
Ottmann, Oliver
Publication Year :: 2017
Publisher :: Nature Publishing Group, 2017.
Abstract: Treatment with azacitidine (AZA), a demethylating agent, prolonged overall survival (OS) vs conventional care in patients with higher-risk myelodysplastic syndromes (MDS). As median survival with monotherapy is

Tools